Aaron E Miller

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. ncbi request reprint Glatiramer acetate in the treatment of multiple sclerosis
    Aaron E Miller
    Department of Neurology, Mt Sinai School of Medicine, New York, NY, USA
    Neurol Clin 23:215-31, viii. 2005
  2. pmc Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
    Aaron E Miller
    Mount Sinai School of Medicine, USA
    Mult Scler 18:1625-32. 2012
  3. doi request reprint Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs
    Aaron E Miller
    Corinne Goldsmith Dikinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, New York 10029, USA
    Curr Opin Neurol 25:S4-10. 2012
  4. doi request reprint Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Aaron Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mult Scler 14:494-9. 2008
  5. doi request reprint Multiple sclerosis: where will we be in 2020?
    Aaron E Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 78:268-79. 2011
  6. ncbi request reprint Immunotherapy of multiple sclerosis--current practice and future directions
    Mark J Tullman
    The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
    J Rehabil Res Dev 39:273-85. 2002
  7. ncbi request reprint Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial
    Jerry S Wolinsky
    Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Ann Neurol 61:14-24. 2007
  8. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
  9. doi request reprint Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009

Detail Information

Publications9

  1. ncbi request reprint Glatiramer acetate in the treatment of multiple sclerosis
    Aaron E Miller
    Department of Neurology, Mt Sinai School of Medicine, New York, NY, USA
    Neurol Clin 23:215-31, viii. 2005
  2. pmc Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis
    Aaron E Miller
    Mount Sinai School of Medicine, USA
    Mult Scler 18:1625-32. 2012
    ....
  3. doi request reprint Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs
    Aaron E Miller
    Corinne Goldsmith Dikinson Center for Multiple Sclerosis, Mount Sinai School of Medicine, New York, New York 10029, USA
    Curr Opin Neurol 25:S4-10. 2012
    ....
  4. doi request reprint Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Aaron Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mult Scler 14:494-9. 2008
    ..0 reached EDSS >or= 6.0. Adverse events were similar to those reported in short-term clinical trials. This study shows a low rate of relapses and EDSS progression in RRMS patients on GA for up to 22 years...
  5. doi request reprint Multiple sclerosis: where will we be in 2020?
    Aaron E Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mt Sinai J Med 78:268-79. 2011
    ..This article addresses current investigative issues and offers predictions about where the understanding and treatment of multiple sclerosis may stand at the end of the 21st century's second decade...
  6. ncbi request reprint Immunotherapy of multiple sclerosis--current practice and future directions
    Mark J Tullman
    The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, Mount Sinai Medical Center, New York, NY 10029, USA
    J Rehabil Res Dev 39:273-85. 2002
    ..Although effective, these therapies have a modest impact on reduction in relapse rate and slowing of disease progression. Much work is needed to improve upon this modest effect and hopefully obtain a cure...
  7. ncbi request reprint Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial
    Jerry S Wolinsky
    Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
    Ann Neurol 61:14-24. 2007
    ..To determine whether glatiramer acetate (GA) slows accumulation of disability in primary progressive multiple sclerosis...
  8. doi request reprint Dose comparison trial of sustained-release fampridine in multiple sclerosis
    A D Goodman
    Multiple Sclerosis Center, Chief Neuroimmunology Unit, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave, Room 6 8521, Box 605, Rochester, NY 14642, USA
    Neurology 71:1134-41. 2008
    ..To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS)...
  9. doi request reprint Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial
    Kathleen Hawker
    Department of Neurology, The Ohio State University Medical Center, Columbus, USA
    Ann Neurol 66:460-71. 2009
    ..We evaluated rituximab in adults with primary progressive MS (PPMS) through 96 weeks and safety through 122 weeks...